Creyon
2 known investors
Creyon develops cell-specific therapeutics using aptamer-delivered oligonucleotides and other payloads (lipid nanoparticles, nucleic acids) for immune-driven diseases, CNS conditions, and genetic disorders. The company combines proprietary aptamer delivery technology with an AI-powered nucleic acid engineering platform to enable targeted therapeutic delivery.
AI & Machine LearningBiotech
Investors Β· 2
Frequently asked questions
- What does Creyon do?
- Creyon develops cell-specific therapeutics using aptamer-delivered oligonucleotides and other payloads (lipid nanoparticles, nucleic acids) for immune-driven diseases, CNS conditions, and genetic disorders. The company combines proprietary aptamer delivery technology with an AI-powered nucleic acid engineering platform to enable targeted therapeutic delivery.
- Who are Creyon's investors?
- Creyon's investors include Lux Capital, Tenmile.